histidine triad nucleotide binding protein 2 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored HINT2P1 profile across patient tissues and cancer cell-line models. HINT2P1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, HINT2P1 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, HINT2P1 RNA expression shows 13,244 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight COAD, BRCA, and GBM as cancer lineages where HINT2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HINT2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HINT2P1 survival associations across molecular data types. HINT2P1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HINT2P1 RNA expression–survival associations across cancer types. High HINT2P1 expression shows unfavorable associations in COAD, SKCM, LUAD and DLBC, but favorable associations in LUSC and PAAD. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for HINT2P1 RNA expression.
This table summarizes HINT2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HINT2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HINT2P1 shows lower tumor expression in BRCA and higher tumor expression in HNSC. The BRCA box plot shows higher HINT2P1 RNA expression in normal versus tumor tissue (log2 FC = −0.034, t-test p = .010).
This table shows molecular features associated with HINT2P1 in patient tissues and cancer cell lines. In patient samples, HINT2P1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
